Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels

25 april 2018 uppdaterad av: Rémi Rabasa-Lhoret, Institut de Recherches Cliniques de Montreal

An Open-label, Double-blind, Randomized, Two-way, Cross-over Pilot Study to Provide Preliminary Evidence of the Efficacy of Rapid-acting Aspart Compared to Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels in Adults With Type 1 Diabetes

Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings.

The objective of this pilot study is to inform both the decision whether to conduct a confirmatory study and the design of the larger confirmatory trial. In addition, we want to estimate postprandial glucose levels parameters and confidence interval in an 11-hour in-patient study with standardized conditions in adults with type 1 diabetes, estimate the size and direction of the treatment effect.

Faster insulin Aspart (FiAsp) will provide preliminary evidence of efficacy to regulate postprandial glucose levels compared to rapid-acting Aspart in adults with type 1 diabetes using insulin pump therapy.

Studieöversikt

Status

Indragen

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Fas

  • Fas 2

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Males and females ≥ 18 years of old.
  2. Clinical diagnosis of type 1 diabetes for at least one year.
  3. The subject will have been on insulin pump therapy for at least 6 months.
  4. HbA1c ≤ 12%.

Exclusion Criteria:

  1. Using a patch-pump (e.g. Omnipod)
  2. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator.
  3. Recent (< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
  4. Ongoing or planned pregnancy.
  5. Breastfeeding.
  6. Severe hypoglycemic episode within two weeks of screening.
  7. Current use of glucocorticoid medication (except low stable dose and inhaled stable treatment).
  8. Known or suspected allergy to the trial products or meal contents.
  9. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
  10. Failure to comply with team's recommendations (e.g. not willing to eat meals/snacks, not willing to change pump parameters, etc).
  11. Problems with venous access.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Rapid-acting Aspart
Rapid-acting Aspart will be used to regulate glucose levels
Enhet: Insulin pump
The participant's insulin pump will be used to infuse insulin
Enhet: Continuous glucose monitoring system
The Dexcom G4 Platinum will be used to measure glucose levels
Övrig: 11-hour intervention with the single-hormone artificial pancreas

Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.

At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.

Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes.
Aktiv komparator: Faster insulin Aspart
Faster insulin Aspart will be used to regulate glucose levels
Enhet: Insulin pump
The participant's insulin pump will be used to infuse insulin
Enhet: Continuous glucose monitoring system
The Dexcom G4 Platinum will be used to measure glucose levels
Övrig: 11-hour intervention with the single-hormone artificial pancreas

Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.

At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.

Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Change in plasma glucose levels 1 hour after the meal
Tidsram: 1 hour
1 hour

Sekundära resultatmått

Resultatmått
Tidsram
Area under the curve of plasma glucose levels for the 1-hour period following the meal.
Tidsram: 1 hour
1 hour
Area under the curve of plasma glucose levels for the 2-hour period following the meal.
Tidsram: 2 hours
2 hours
Plasma glucose level 1 hour after the meal.
Tidsram: 1 hour
1 hour
Plasma glucose level 2 hours after the meal.
Tidsram: 2 hours
2 hours
Glycemic peak in the 3 hours following the meal.
Tidsram: 3 hours
3 hours
Change in plasma glucose levels 2 hours after the meal.
Tidsram: 2 hours
2 hours
Peak time of glucose levels over the 4 hours following the meal.
Tidsram: 4 hours
4 hours
Number of hypoglycemic events less than 4.0 mmol/L over the 4 hours following the meal.
Tidsram: 4 hours
4 hours
Percentage of time of plasma glucose levels between 3.9 and 7.8 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of sensor glucose levels between 3.9 and 7.8 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of plasma glucose levels between 3.9 and 10 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of sensor glucose levels between 3.9 and 10 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of plasma glucose levels below 3.9 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of sensor glucose levels below 3.9 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of plasma glucose levels below 3.3 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of sensor glucose levels below 3.3 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of plasma glucose levels below 2.8 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of sensor glucose levels below 2.8 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of plasma glucose levels above 10 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of sensor glucose levels above 10 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of plasma glucose levels above 13.9 mmol/L
Tidsram: 11 hours
11 hours
Percentage of time of sensor glucose levels above 13.9 mmol/L
Tidsram: 11 hours
11 hours
Percentage of time of plasma glucose levels above 16.7 mmol/L.
Tidsram: 11 hours
11 hours
Percentage of time of sensor glucose levels above 16.7 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of plasma glucose levels below 3.9 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of sensor glucose levels below 3.9 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of plasma glucose levels below 3.3 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of sensor glucose levels below 3.3 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of plasma glucose levels below 2.8 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of sensor glucose levels below 2.8 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of plasma glucose levels above 10.0 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of sensor glucose levels above 10.0 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of plasma glucose levels above 13.9 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of sensor glucose levels above 13.9 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of plasma glucose levels above 16.7 mmol/L.
Tidsram: 11 hours
11 hours
Area under the curve of sensor glucose levels above 16.7 mmol/L.
Tidsram: 11 hours
11 hours
Standard deviation of plasma glucose levels.
Tidsram: 11 hours
11 hours
Standard deviation of sensor glucose levels.
Tidsram: 11 hours
11 hours
Coefficient of variance of plasma glucose levels.
Tidsram: 11 hours
11 hours
Coefficient of variance of sensor glucose levels.
Tidsram: 11 hours
11 hours
Total insulin delivery.
Tidsram: 11 hours
11 hours
Mean plasma glucose level.
Tidsram: 11 hours
11 hours
Mean sensor glucose level.
Tidsram: 11 hours
11 hours
Mean plasma insulin concentration.
Tidsram: 11 hours
11 hours
Number of hypoglycemic events less than 3.3 mmol/L (>20 minutes).
Tidsram: 11 hours
11 hours

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Institut de Recherches Cliniques de Montreal

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Förväntat)

1 april 2018

Primärt slutförande (Förväntat)

31 december 2018

Avslutad studie (Förväntat)

31 december 2018

Studieregistreringsdatum

Först inskickad

3 november 2017

Först inskickad som uppfyllde QC-kriterierna

3 november 2017

Första postat (Faktisk)

7 november 2017

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

27 april 2018

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

25 april 2018

Senast verifierad

1 april 2018

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • CLASS-FiAsp

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Typ 1-diabetes mellitus

Kliniska prövningar på Insulin pump

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Hungary

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

Prenumerera